Myasth¡§|nie du?sujet ag¡§| : diagnostic, comorbidit¡§| et?¡§|volution: ¡§¡è propos de 45 cas
详细信息    查看全文
文摘
| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Objective

Analyze the clinical presentation, laboratory indicators, and outcome of patients with late-onset myasthenia gravis (after 60 years).

Method

This retrospective cohort design with prospective follow-up included 45 patients with late-onset myasthenia gravis diagnosed in hospitals in Avignon, Montpellier, and Nimes between 1993 and 2000. Prospective data collection of their subsequent course took place in 2001.

Results

Median age at onset was 72 years and median follow-up 35.5 months. Initial symptoms were ocular (38/45, 95 % ) and bulbar (31/45, 69 % ). Initial Osserman grades were distributed as follows: 10 grade I, 2 grade IIA, 25 grade IIB, 8 grade III and no grade IV. Anticholinesterase antibodies were positive in 39 patients (91 % ), response to anticholinesterase positive in 31/33 (94 % ), and electrophysiological abnormalities observed in 20/33 (61 % ). Thoracic computed tomography, performed in 42 patients (93 % ), found thymic abnormalities in 7. At least one comorbid disease was diagnosed in 41/43 patients (93 % ) and an autoimmune disorder in 18/43 (42 % ). In all, 42 patients (93 % ) received anticholinesterase and 36 (80 % ) immunosuppressive therapy. Sixteen patients (36 % ) died during follow-up, 8 of causes directly related to the myasthenia gravis. The relative risk of death estimated by odds ratios (OR) was highest for patients with comorbid cancer (OR 8.6 [1.8-40.6]) and those with the highest Osserman scores: grades I-II OR: 0.05 [0.01-0.29] versus grades III-IV OR: 15.5 [2.9-83.0].

Conclusion

Late-onset myasthenia gravis is specific in many aspects (presentation, autoimmune and other comorbid conditions, and course) that require attentive care.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700